[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201170527A1 - Фармацевтические композиции, включающие соединения бороновой кислоты - Google Patents

Фармацевтические композиции, включающие соединения бороновой кислоты

Info

Publication number
EA201170527A1
EA201170527A1 EA201170527A EA201170527A EA201170527A1 EA 201170527 A1 EA201170527 A1 EA 201170527A1 EA 201170527 A EA201170527 A EA 201170527A EA 201170527 A EA201170527 A EA 201170527A EA 201170527 A1 EA201170527 A1 EA 201170527A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
boronic acid
acid compounds
compositions
bortezomib
Prior art date
Application number
EA201170527A
Other languages
English (en)
Inventor
Чандрасекхар Кочерлакота
Лавания Налламотху
Кришнам Раджу Ковору
Нагараджу Банда
Миттапалли Сридхар
Кени Девендра Чандркантх
Соогаредди Чаннаредди Шантредди
Вагх Санджай Чхаган
Равирадж Сукумар Пиллаи
Бандари Среедхар
Хинге Крантхикумар
Original Assignee
Др. Редди'С Лабораторис Лтд.
Др. Редди'С Лабораторис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Редди'С Лабораторис Лтд., Др. Редди'С Лабораторис, Инк. filed Critical Др. Редди'С Лабораторис Лтд.
Publication of EA201170527A1 publication Critical patent/EA201170527A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Фармацевтические композиции, включающие бортезомиб, для перорального или парентерального введения. Конкретные аспекты относятся к стабильным, не содержащим сахара фармацевтическим композициям бортезомиба, включая его фармацевтически приемлемые соли или сольваты, в виде готовых для применения растворов, лиофилизованных форм или физических смесей и их препаратов. Другие аспекты относятся к способам получения композиций и способам применения композиций для лечения различных видов рака у млекопитающих.
EA201170527A 2008-10-01 2009-09-30 Фармацевтические композиции, включающие соединения бороновой кислоты EA201170527A1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN2415CH2008 2008-10-01
IN3160CH2008 2008-12-16
US14128708P 2008-12-30 2008-12-30
US14855509P 2009-01-30 2009-01-30
IN363CH2009 2009-02-18
US18526309P 2009-06-09 2009-06-09
PCT/US2009/058929 WO2010039762A2 (en) 2008-10-01 2009-09-30 Pharmaceutical compositions comprising boronic acid compounds

Publications (1)

Publication Number Publication Date
EA201170527A1 true EA201170527A1 (ru) 2011-10-31

Family

ID=42074166

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170527A EA201170527A1 (ru) 2008-10-01 2009-09-30 Фармацевтические композиции, включающие соединения бороновой кислоты

Country Status (4)

Country Link
US (1) US20110178470A1 (ru)
EP (1) EP2344165A4 (ru)
EA (1) EA201170527A1 (ru)
WO (1) WO2010039762A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
JP5661912B2 (ja) 2010-03-18 2015-01-28 イノファーマ，インコーポレイテッド 安定なボルテゾミブ製剤
CA2813003A1 (en) * 2010-10-05 2012-04-12 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
ES2655642T3 (es) 2011-05-16 2018-02-21 Ulrike Nuber Terapias contra el cáncer novedosas y métodos
WO2013128419A2 (en) * 2012-03-02 2013-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
WO2014102755A1 (en) * 2012-12-31 2014-07-03 Shilpa Medicare Limited Bortezomib formulations
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
ZA201402789B (en) * 2013-04-16 2015-11-25 Cipla Ltd Process for the preparation of bortezomib mannitol ester
CN103212055B (zh) * 2013-04-19 2014-11-05 海南锦瑞制药股份有限公司 一种硼替佐米的药物组合物及其制备方法
WO2015117136A1 (en) 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
WO2016001905A2 (en) * 2014-07-04 2016-01-07 Dr. Reddy’S Laboratories Limited Stable liquid ready-to-use injectable formulation of bortezomib
EP3031811A1 (en) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Malic acid esters of bortezomib
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
WO2016166653A1 (en) * 2015-04-13 2016-10-20 Leiutis Pharmaceuticals Pvt Ltd Stable liquid pharmaceutical compositions of bortezomib
GB2554008A (en) * 2015-04-13 2018-03-21 Leiutis Pharm Pvt Ltd Stable liquid pharmaceutical compositions of bortezomib
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
US10314880B2 (en) * 2015-08-06 2019-06-11 Ftf Pharma Private Limited Composition comprising bortezomib
CN107224569A (zh) * 2016-03-26 2017-10-03 复旦大学 一种硼替佐米水溶性药用组合物及其制备方法和用途
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
CN108201622A (zh) * 2016-12-16 2018-06-26 宁波宁融生物医药有限公司 一种硼替佐米药物组合物及其应用
EP3908258A4 (en) * 2019-01-11 2022-09-28 Intas Pharmaceuticals Ltd. METHOD FOR PREPARING A STABLE PHARMACEUTICAL COMPOSITION OF BORTEZOMIB
WO2022094396A1 (en) 2020-11-02 2022-05-05 Spes Pharmaceuticals Inc. Aqueous compositions of bortezomib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
EP1425311A4 (en) * 2001-01-11 2004-12-01 Eastman Chem Co CYCLODEXTRINSULFONATES, GUEST INCLUDING COMPLEXES, METHOD FOR THEIR PRODUCTION AND RELATED MATERIALS
TR201819416T4 (tr) * 2001-01-25 2019-01-21 The United States Of America Represented By The Sec Dep Of Health And Human Services Boronik asit bileşiklerinin formülasyonu.
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
CA2589921C (en) * 2004-12-07 2016-01-26 Proteolix, Inc. Composition comprising a cyclodextrin and a proteasome inhibitor
AR057227A1 (es) * 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
WO2008066783A2 (en) * 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a

Also Published As

Publication number Publication date
WO2010039762A2 (en) 2010-04-08
WO2010039762A3 (en) 2010-07-15
EP2344165A4 (en) 2012-12-05
US20110178470A1 (en) 2011-07-21
EP2344165A2 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
IL197393A (en) History of pyridine-4-ram, containing and using pharmaceutical preparations for the preparation of drugs for the treatment of immune-related diseases
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2009010977A (es) Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
WO2006077025A3 (en) Morpholines as 5ht2c agonists
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
TW200626558A (en) Indazolone derivatives
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия